Celastrol (CEL), an IL-2/CD25 binding inhibitor, impacts melanoma treatment by blocking IL-2 from interacting with the CD25 receptor, thereby disrupting IL-2 signaling in T cells. This evidence concerns the gene IL2RA and melanoma.